Scholar Rock gets first FDA nod for rare muscle-wasting disease - Reuters
Scholar Rock gets first FDA nod for rare muscle-wasting disease Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPVU5NMExYODNrTUtaUGJWeGhmcDI4UmVHaWZEU2M4Tkc5Mkd1MHVSMmJhOXlDeEdQZE1JTW0xa0lyV1A4U2gwMmEzMzl6TW5lb25zaGlWTXAwc3g5S2Q0U2Y0NG01bzk3Z2kyRE5UcENFSmUyVlFwcHo3Y2JYYks0S29nRkpsakIxSDZfdV9xeHJITlVGUkU4cE9IeHpIU2FnOFc2b1p1RUdibS1OakFBMEQ2bUZDakhRQmhXRXJVdw?oc=5" target="_blank">Scholar Rock gets first FDA nod for rare muscle-wasting disease</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Boots has a new owner: Three ways it could affect you
The stalwart of Britain's High Street has been sold to a Canadian billionaire family. What will that mean for you?
October 9, 2026 at 11:01 PMReport highlights flaws in ADHD and autism care
There is a risk of people being over-diagnosed with ADHD and autism, an official review in England has found.
October 9, 2026 at 01:52 PMHumana surges after topping 2027 Medicare star ratings - Reuters
Humana surges after topping 2027 Medicare star ratings Reuters
October 9, 2026 at 01:33 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMMost Medicare Advantage drug plan enrollees in high-quality plans, US government says - Reuters
Most Medicare Advantage drug plan enrollees in high-quality plans, US government says Reuters
October 8, 2026 at 11:29 PMADHD and autism at risk of over-diagnosis, says government review
The review, which focuses on younger people, warned there was a risk society was moving from an era of under-diagnosis to over-diagnosis.
October 8, 2026 at 11:01 PM